A multiple ascending dose (MAD) study of R547 administered as an intravenous infusion on a weekly schedule in patients with advanced solid tumors.
Phase of Trial: Phase I
Latest Information Update: 23 May 2013
At a glance
- Drugs R 547 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 23 Feb 2010 Actual patient number (58) added as reported by Roche.
- 23 Feb 2010 New source identified and integrated (Roche record).
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche.